A randomized phase II trial of docetaxel and doxorubicin in treatment for patients with non-small-cell lung cancer who have failed previous platinum-based chemotherapy

The aim of this study was to evaluate the efficacy, toxicity and safety of doxorubicin combined with domestically produced docetaxel versus with taxotere, and to investigate whether these two regimens result in similar outcomes in the treatment for non-small-cell lung cancer (NSCLC) patients who fai...

Full description

Saved in:
Bibliographic Details
Published inZhōnghuá zhŏngliú zázhì Vol. 30; no. 6; p. 465
Main Authors Wang, Zi-ping, Sun, Yan, Zhang, Xiang-ru, Zhang, Mao-hong, Wang, Xiu-wen, Yu, Xue-jun, Nan, Ke-jun, Li, En-xiao, Liu, Ji-wei, Gao, Ya-jie, Guan, Xiao-qian, Song, Shu-ping, Sheng, Li-jun, Wang, Dong-lin, Wang, Zhi-xin
Format Journal Article
LanguageChinese
Published China 01.06.2008
Subjects
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - pathology
Doxorubicin - administration & dosage
Female
Humans
Leukopenia - chemically induced
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Male
Middle Aged
Neoplasm Staging
Neutropenia - chemically induced
Remission Induction
Salvage Therapy
Taxoids - administration & dosage
Treatment Failure
Vomiting - chemically induced
Online AccessGet more information

Cover

More Information
Summary:The aim of this study was to evaluate the efficacy, toxicity and safety of doxorubicin combined with domestically produced docetaxel versus with taxotere, and to investigate whether these two regimens result in similar outcomes in the treatment for non-small-cell lung cancer (NSCLC) patients who failed previous platinum-based chemotherapy. Eighty-eight NSCLC patients were enrolled into this clinical phase II trial. The patients randomly received either domestic docetaxel (study arm) or taxotere (control arm) at a dose of 70 mg/m2 on D2, while doxorubicin at a dose of 40 mg/m2 on D1 was administered in both groups. It was repeated every 3 weeks, totally for three cycles. No granulocyte colony-stimulating factor was used to prevent granulocytopenia. The response rate and toxicity were evaluated using World Health Organization toxicity scale and Karnofsky performance status scale. Of the 88 patients, 81 were evaluable in terms of efficacy. There was no complete responder in this series. The response rate (RR) wa
ISSN:0253-3766